Skip to content

Teva Pharmaceutical Industries

US · TEVA #471 by market cap Listed 1970
39.23 +0.69 +1.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 04:43 UTC.

FormFiledOriginal document
8-K2026-11-18Read on SEC.gov
10-Q2026-11-03Read on SEC.gov
8-K2026-11-03Read on SEC.gov
8-K2026-10-29Read on SEC.gov
8-K2026-09-16Read on SEC.gov
8-K2026-09-14Read on SEC.gov
8-K2026-09-11Read on SEC.gov
8-K2026-09-03Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 16:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$17.26BAnnual2025-12-312026-02-0310-K
Net income$1.41BAnnual2025-12-312026-02-0310-K
Operating cash flow$1.65BAnnual2025-12-312026-02-0310-K
Total assets$40.75BAs of2025-12-312026-02-0310-K
Total liabilities$32.83BAs of2025-12-312026-02-0310-K
Stockholders’ equity$7.91BAs of2025-12-312026-02-0310-K
Cash and cash equivalents$3.56BAs of2025-12-312026-02-0310-K

✦ Quant Financial Health how this is computed

Weak
  • Altman Z-Score is 1.12, below the 1.8 "distress zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Generic products (including biosimilars) is the largest reported line at 57.06% of revenue, across 8 reported segments.
  • AUSTEDO follows at 19.86%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 8 years

Latest year +4.32% YoY

Margins

Gross margin
51.79%
Operating margin
22.90%
Net margin
8.17%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 18.27B16.89B16.66B15.88B14.93B15.85B16.54B17.26B
Gross profit 8.30B7.54B7.73B7.59B6.97B7.65B8.06B8.94B
Selling & admin expenses 4.21B3.81B3.67B3.53B3.45B3.50B3.70B3.97B
Research & development 1.21B1.01B997.00M967.00M838.00M953.00M998.00M1.01B
Operating profit 2.87B2.72B3.06B3.10B2.69B3.19B3.36B3.95B
Pretax profit -2.60B-1.27B-4.41B658.00M-3.16B-624.00M-1.28B1.22B
Tax -195.00M-278.00M-168.00M211.00M-643.00M-7.00M676.00M-180.00M
Net profit -2.47B-1.00B-4.10B456.00M-2.50B-615.00M-1.96B1.42B
Basic EPS -2-1-40-2-1-11
Diluted EPS -2.35-0.91-3.640.38-2.20-0.50-1.451.21

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 13.79B13.46B13.01B12.57B12.05B12.49B12.55B13.95B
Cash & ST investments 1.78B1.98B2.18B2.17B2.80B3.23B3.30B3.56B
Inventory 4.73B4.42B4.40B3.82B3.83B4.02B3.01B3.18B
Total assets 60.68B57.47B50.64B47.67B44.01B43.48B39.33B40.75B
Total current liabilities 14.32B13.67B13.16B11.03B11.47B12.25B12.80B13.46B
Short-term debt 2.22B2.35B3.19B1.43B2.11B1.67B1.78B1.82B
Long-term debt 26.70B24.56B22.73B21.62B19.10B18.16B16.00B14.99B
Total liabilities 44,889,000,000.0042,407,000,000.0039,579,000,000.0036,422,000,000.0035,413,000,000.0035,353,000,000.0033,606,000,000.0032,834,000,000.00
Total equity 15.79B15.06B11.06B11.24B8.60B8.13B5.72B7.91B
Retained earnings -5.96B-6.96B-10.95B-10.53B-12.98B-13.53B-15.17B-13.76B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 2.45B748.00M1.22B798.00M1.59B1.37B1.25B1.65B
Depreciation & amortization 1.84B1.72B1.56B1.33B1.31B1.15B1.06B1.00B
Free cash flow 1.80B223.00M638.00M236.00M1.04B842.00M749.00M1.15B
Dividends paid ----------------
Stock buybacks / issuance ----------------
Ending cash balance 1.78B1.98B2.18B2.20B2.83B3.23B3.30B3.56B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % -16.87-6.97-33.254.11-25.89-7.26-25.4521.23
ROA % -3.65-1.69-7.380.85-5.13-1.28-3.963.52
ROIC % -3.46-0.73-7.893.31-5.121.61-3.398.73
5-year avg ROE % -14.61-18.67-26.58-25.81-16.01-14.09-17.79-6.89
EBIT margin % -8.89-2.27-20.679.75-14.302.56-1.7012.40
FCF / sales % 9.521.323.831.496.985.314.536.65
Current ratio 0.960.980.991.141.051.020.981.04
Quick ratio 0.530.560.510.610.570.540.500.54
Debt / assets 47.6547.5852.1349.2248.9946.3545.9741.95
LT debt / equity 181.55178.91231.50214.37249.26246.22303.33193.10
Interest coverage -1.82-0.44-3.581.74-2.300.39-0.282.34
Revenue CAGR (3Y) % -2.40-8.30-8.65-4.57-4.03-1.651.384.96
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % -27.80-57.90-22.13-49.1567.189.6946.963.28

Revenue breakdown most recent period

Business

Generic products (including biosimilars)57.06%
AUSTEDO19.86%
Other8.73%
AJOVY7.14%
COPAXONE2.75%
UZEDY2.25%
Respiratory products1.43%
BENDEKA and TREANDA0.79%

Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.

Teva Pharmaceutical Industries discussion 0 comments

Add a comment